Vertex Pharmaceuticals VRTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's investing cash flow?
- Vertex Pharmaceuticals (VRTX) reported investing cash flow of -$431.9M in Q1 2026.
- How has Vertex Pharmaceuticals's investing cash flow changed year-over-year?
- Vertex Pharmaceuticals's investing cash flow decreased by 674.0% year-over-year, from -$55.8M to -$431.9M.
- What is the long-term trend for Vertex Pharmaceuticals's investing cash flow?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's investing cash flow has grown at a 40.5% compound annual growth rate (CAGR), from -$340.9M to -$945.4M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.